Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey
Improving the lives of our patients
We work tirelessly to deliver meaningful therapeutics for the patients we serve.
Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey
Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D
Servier receives a positive CHMP opinion for ONIVYDE® in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as first line therapy in patients with metastatic pancreatic adenocarcinoma.